NeuroSense Therapeutics Ltd.
NRSN
$1.08
-$0.72-40.00%
NASDAQ
| 12/31/2024 | 06/30/2024 | 12/31/2023 | 09/30/2023 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | -- | -- | 4.37M | 3.65M | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | -- | -- | 11.40M | 9.75M | |
| Operating Income | -- | -- | -11.40M | -9.75M | |
| Income Before Tax | -- | -- | -9.14M | -8.67M | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -- | -- | -9.14 | -8.67 | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -- | -- | -9.14M | -8.67M | |
| EBIT | -- | -- | -11.40M | -9.75M | |
| EBITDA | -- | -- | -11.38M | -9.73M | |
| EPS Basic | -- | -- | -0.70 | -0.71 | |
| Normalized Basic EPS | -- | -- | -0.20 | -0.21 | |
| EPS Diluted | -- | -- | -0.70 | -0.71 | |
| Normalized Diluted EPS | -- | -- | -0.20 | -0.21 | |
| Average Basic Shares Outstanding | -- | -- | 54.56M | 49.23M | |
| Average Diluted Shares Outstanding | -- | -- | 54.56M | 49.23M | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |